Home › Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
 

Keywords :   


Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet

2013-03-27 13:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet (AIT) has been accepted for review by the U.S. Food and Drug Administration (FDA). In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT. Language:  English Contact HTML:  MerckMedia:Pam Eisele, (908) 423-5042Tracy Ogden, (267) 305-2301orInvestors:Justin Holko, (908) 423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: application license acceptance grass

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
28.09Hurricane Isaac Public Advisory Number 12
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Tropical Storm Joyce Wind Speed Probabilities Number 6
More »